PE20140036A1 - Metodos y composiciones para tratar diarrea asociada con vih - Google Patents

Metodos y composiciones para tratar diarrea asociada con vih

Info

Publication number
PE20140036A1
PE20140036A1 PE2013000926A PE2013000926A PE20140036A1 PE 20140036 A1 PE20140036 A1 PE 20140036A1 PE 2013000926 A PE2013000926 A PE 2013000926A PE 2013000926 A PE2013000926 A PE 2013000926A PE 20140036 A1 PE20140036 A1 PE 20140036A1
Authority
PE
Peru
Prior art keywords
hiv
diarrhea
compositions
methods
treat hiv
Prior art date
Application number
PE2013000926A
Other languages
English (en)
Spanish (es)
Inventor
William Forbes
Enoch Bortey
Steven King
Pravin Chaturvedi
Original Assignee
Napo Pharmaceuticals Inc
Salix Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45994461&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20140036(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Napo Pharmaceuticals Inc, Salix Pharmaceuticals Ltd filed Critical Napo Pharmaceuticals Inc
Publication of PE20140036A1 publication Critical patent/PE20140036A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
PE2013000926A 2010-10-31 2011-10-31 Metodos y composiciones para tratar diarrea asociada con vih PE20140036A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US40862210P 2010-10-31 2010-10-31
US40933510P 2010-11-02 2010-11-02
US41624910P 2010-11-22 2010-11-22
US201161434379P 2011-01-19 2011-01-19

Publications (1)

Publication Number Publication Date
PE20140036A1 true PE20140036A1 (es) 2014-01-31

Family

ID=45994461

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013000926A PE20140036A1 (es) 2010-10-31 2011-10-31 Metodos y composiciones para tratar diarrea asociada con vih

Country Status (20)

Country Link
US (4) US8962680B2 (https=)
EP (1) EP2632550B1 (https=)
JP (2) JP6063385B2 (https=)
CN (2) CN107595836A (https=)
AU (1) AU2011320155B2 (https=)
BR (1) BR112013010774A2 (https=)
CA (1) CA2816416C (https=)
DK (1) DK2632550T3 (https=)
EC (1) ECSP13012650A (https=)
ES (1) ES2635435T3 (https=)
HK (1) HK1249036A1 (https=)
HU (1) HUE035393T2 (https=)
MX (1) MX348184B (https=)
PE (1) PE20140036A1 (https=)
PH (1) PH12013500857A1 (https=)
PL (1) PL2632550T3 (https=)
PT (1) PT2632550T (https=)
RU (1) RU2597746C2 (https=)
WO (1) WO2012058664A1 (https=)
ZA (1) ZA201303136B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2241318T1 (sl) 2006-05-01 2013-04-30 Napo Pharmaceuticals, Inc. Postopek za zdravljenje sindroma iritabilnega ÄŤrevesa s predominantno obstipacijo
ES2616012T3 (es) 2006-05-01 2017-06-09 Napo Pharmaceuticals, Inc. Composiciones para tratar o prevenir enfermedad inflamatoria del intestino
US20070254050A1 (en) 2006-05-01 2007-11-01 Quart Barry D Method for treatment of diarrhea-predominant irritable bowel syndrome
CN107595836A (zh) 2010-10-31 2018-01-19 纳珀制药公司 用于治疗hiv相关性腹泻的方法和组合物
EP2928560A4 (en) * 2012-12-07 2016-06-01 Salix Pharmaceuticals Inc METHODS AND COMPOSITIONS FOR THE TREATMENT OF HIV-ASSOCIATED DIARRHEA
US11389424B2 (en) 2017-03-09 2022-07-19 Napo Pharmaceuticals, Inc. Methods and compositions for treating chemotherapy-induced diarrhea
JP7328153B2 (ja) 2017-05-31 2023-08-16 ナポ ファーマシューティカルズ インク． 胆汁酸性下痢、小腸切除又は胆嚢除去及び短腸症候群に関連する下痢を治療するための方法及び組成物
US11857510B2 (en) 2017-05-31 2024-01-02 Napo Pharmaceuticals, Inc. Methods and compositions for treating congenital diarrhea disorder
EP3935581A4 (en) 2019-03-04 2022-11-30 Iocurrents, Inc. DATA COMPRESSION AND COMMUNICATION USING MACHINE LEARNING
CA3182864A1 (en) * 2020-06-19 2021-12-23 Lisa A. CONTE Methods and compositions for treating chemotherapy-induced diarrhea
WO2022115481A1 (en) * 2020-11-24 2022-06-02 Napo Pharmaceuticals, Inc. Methods and compositions for treating post-acute infection gastrointestinal disorders

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5211944A (en) 1990-10-12 1993-05-18 Shaman Pharmaceuticals, Inc. Proanthocyanidin polymers having antiviral activity and methods of obtaining same
EP2060183A3 (en) 1996-10-16 2009-06-03 Napo Pharmaceuticals, Inc. Enteric formulations of proanthocyanidin polymer antidiarrheal compositions
WO2000047062A2 (en) * 1999-02-01 2000-08-17 Shaman Pharmaceuticals, Inc. Enteric formulations of proanthocyanidin polymer dietary supplements and methods for preparing same
US20040071793A1 (en) 2002-10-05 2004-04-15 Bobrowski Paul J. Oral rehydration methods and compositions
WO2005074575A2 (en) * 2004-01-30 2005-08-18 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
JP2008546790A (ja) * 2005-06-22 2008-12-25 ユニバーシティー オブ マサチューセッツ Ｈｉｖ−１プロテアーゼ阻害剤
CA2633417A1 (en) 2005-12-15 2007-06-21 Bayer Healthcare Ag Diaryl ureas for treating virus infections
SI2241318T1 (sl) * 2006-05-01 2013-04-30 Napo Pharmaceuticals, Inc. Postopek za zdravljenje sindroma iritabilnega ÄŤrevesa s predominantno obstipacijo
ES2616012T3 (es) 2006-05-01 2017-06-09 Napo Pharmaceuticals, Inc. Composiciones para tratar o prevenir enfermedad inflamatoria del intestino
US20070254050A1 (en) 2006-05-01 2007-11-01 Quart Barry D Method for treatment of diarrhea-predominant irritable bowel syndrome
US20100092479A1 (en) 2008-08-18 2010-04-15 Combinatorx (Singapore) Pte. Ltd. Compositions and methods for treatment of viral diseases
US7928115B2 (en) 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
WO2011024049A2 (en) 2009-08-26 2011-03-03 Glenmark Pharmaceuticals Ltd Method for producing proanthocyanidin polymer compositions for pharmaceutical formulations
AU2010303577B2 (en) 2009-10-06 2015-10-22 Napo Pharmaceuticals, Inc. Methods of treating diseases with proanthocyanidin oligomers such as crofelemer
US20110087530A1 (en) 2009-10-09 2011-04-14 Visa U.S.A. Inc. Systems and Methods to Provide Loyalty Programs
CN107595836A (zh) 2010-10-31 2018-01-19 纳珀制药公司 用于治疗hiv相关性腹泻的方法和组合物
WO2012101008A1 (en) 2011-01-27 2012-08-02 Glenmark Pharmaceuticals Limited Process for the production of proanthocyanidin polymeric composition
BR112014015314A2 (pt) 2011-12-22 2017-06-13 Glenmark Pharmaceuticals Ltd composição farmacêutica não entérica compreendendo crofelemer
EP2928560A4 (en) 2012-12-07 2016-06-01 Salix Pharmaceuticals Inc METHODS AND COMPOSITIONS FOR THE TREATMENT OF HIV-ASSOCIATED DIARRHEA

Also Published As

Publication number Publication date
US8962680B2 (en) 2015-02-24
EP2632550B1 (en) 2017-05-03
CN103370101A (zh) 2013-10-23
RU2013123794A (ru) 2014-12-10
WO2012058664A1 (en) 2012-05-03
MX2013004873A (es) 2013-08-21
US20120107370A1 (en) 2012-05-03
MX348184B (es) 2017-06-02
HUE035393T2 (en) 2018-05-02
ES2635435T3 (es) 2017-10-03
DK2632550T3 (en) 2017-08-07
AU2011320155B2 (en) 2016-02-25
CA2816416A1 (en) 2012-05-03
CA2816416C (en) 2020-02-11
US20140294903A1 (en) 2014-10-02
US9585868B2 (en) 2017-03-07
EP2632550A4 (en) 2014-04-23
US20120184605A1 (en) 2012-07-19
ECSP13012650A (es) 2013-10-31
EP2632550A1 (en) 2013-09-04
PH12013500857A1 (en) 2018-01-17
PL2632550T3 (pl) 2017-10-31
JP2017019806A (ja) 2017-01-26
JP6310971B2 (ja) 2018-04-11
JP2013540826A (ja) 2013-11-07
ZA201303136B (en) 2016-01-27
AU2011320155A1 (en) 2013-05-09
HK1249036A1 (zh) 2018-10-26
JP6063385B2 (ja) 2017-01-18
US20150190367A1 (en) 2015-07-09
RU2597746C2 (ru) 2016-09-20
CN107595836A (zh) 2018-01-19
PT2632550T (pt) 2017-08-02
BR112013010774A2 (pt) 2017-03-21

Similar Documents

Publication Publication Date Title
PE20140036A1 (es) Metodos y composiciones para tratar diarrea asociada con vih
CL2021001292A1 (es) Terapia de combinación que incluye un inhibidor de krasg12c y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cánceres
JOP20220008A1 (ar) مثبطات parp1
MX2020005909A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo.
DOP2015000234A (es) COMPOSICIONES DE ARNi CONTRA EL COMPONENTE C5 DEL COMPLEMENTO Y METODOS PARA SU USO.
CO2017001493A2 (es) Kits que comprenden inhibidores tigit y agentes anticáncer
MX2018000981A (es) Composiciones de acido ribonucleico interferente (arni) de transtiretina (ttr) y metodos para su uso para el tratamiento o prevencion de enfermedades asociadas con transtiretina (ttr).
CL2020000220A1 (es) Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial.
MX2022012079A (es) Metodos y composiciones para mantener la salud renal.
ECSP12011735A (es) Composiciones que comprenden tramadol y celecoxib en el tratamiento del dolor
MX383254B (es) Combinacion que comprende un glucocorticoide y edo-s101.
MX2021013354A (es) Metodos para tratar y/o prevenir queratosis actinica.
MY175764A (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
PE20200794A1 (es) Composicion para su uso en la prevencion y el tratamiento de patologias del aparato cardiovascular
CO2022000270A2 (es) Inhibidores de enzimas
MX2013007735A (es) Fibra y probioticos para reducir sintomas intestinales relacionados con estres cronico.
CL2020000221A1 (es) Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial.
ZA201906153B (en) Pharmaceutical compositions for combination therapy
MX2020000694A (es) Composiciones que comprenden darunavir, cobicistat, emtricitabine y alafenamida de tenofovir para usar en el tratamiento del vih.
MX2020001399A (es) Agentes antifungicos con actividad mejorada en ph acido.
MX2019015273A (es) Moduladores de alfa-sinucleinca.
CO6640306A2 (es) Combinación de inhibidores de xantina oxidasa y antagonistas del receptor de angiotensina ii y su uso
MX383214B (es) COMPOSICIONES Y MÉTODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) PARA AUMENTAR LA RECUPERACIÓN DE TRAUMA DE TEJIDO BLANDO.
MY174065A (en) Methods and compositions for treating hiv-associated diarrhea
UA109763C2 (ru) Способ лечения паховых и пахово-мошоночных грыж у новорожденных и мальчиков младшей возрастной группы

Legal Events

Date Code Title Description
FC Refusal